StreetAlpha.app
Home › Stocks › ENGN

enGene Therapeutics Inc. (ENGN)

Members
LATEST PRICE

enGene Therapeutics develops genetic medicines, led by detalimogene, a product candidate for a type of bladder cancer. ENGN reports earnings on Tue, Dec 22, 2026.

Prices, price targets and earnings estimates for ENGN are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is ENGN in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Dec 22
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ENGN in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for ENGNThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
HC Wainwright & Co.Reiterated
Sep 8Buy
HC Wainwright & Co.Maintained
Jun 16Buy
Wells FargoDowngrade
May 8Hold
Piper SandlerDowngrade
May 8Hold
WBB SecuritiesInitiated
Apr 13Buy
DateFirmActionRatingPrice target
Sep 8HC Wainwright & Co.ReiteratedBuy
Jun 16HC Wainwright & Co.MaintainedBuy
May 8Wells FargoDowngradeHold
May 8Piper SandlerDowngradeHold
Apr 13WBB SecuritiesInitiatedBuy
Loading…

Whale Options Flow

90D

No whale options trades in ENGN in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENGN is in one of them and how their past ENGN trades turned out.

See how it works→ View all auto pilots→
ENGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ENGN in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About enGene Therapeutics

enGene Therapeutics is a biotechnology company based in Saint-Laurent that develops genetic medicines. Its main product candidate, detalimogene, is intended for patients with a form of bladder cancer that no longer responds to BCG treatment. The company is also building a delivery platform that carries genetic medicines to mucosal tissues, with plans to apply it to other conditions such as urogenital and gastrointestinal diseases. Its products are still in preclinical and clinical development and are not yet approved for sale.

Headquarters
Saint-Laurent
Summary based on the company’s 2025 annual report (10-K) ↗